Established in December 2000, WuXi AppTec is a leading global pharmaceutical and medical device open-access capability and technology platform company with global operations. With its industry-leading capabilities such as small molecule drug R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, drug R&D and medical device testing, WuXi platform is enabling more than 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated".
Enabling more than 3,000 Innovative Collaborators from more than 30 Countries
Small Molecule Drug R&D and Manufacturing
Cell Therapy
and Gene Therapy
Drug R&D and Medical
Device Testing
Clinical
Services
Small Molecule Drug R&D and Manufacturing
To Become the Most Comprehensive Capability and Technology Platform in the Global Pharmaceutical and Healthcare Industry
WuXi AppTec Appoints Dr. Frederick H. Hausheer as Chief Medical Officer
WuXi STA’s New Drug Product Manufacturing Facility Passes First European MPA GMP Inspection
WuXi AppTec Reports Strong 2018 Annual Results
WuXi AppTec Testing Facilities Complete Three Regulatory Inspections from US FDA, OECD, and CNAS with Excellent Results
The first WuXi Healthcare Forum opens in Shanghai
WuXi STA and BioLingus sign exclusive technology and marketing collaboration for sublingual delivery
